These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27054986)

  • 1. Ignore the Delaware director-compensation cases at your peril.
    Lilienfeld D; Polovoy B; Kessel M
    Nat Biotechnol; 2016 Apr; 34(4):373-4. PubMed ID: 27054986
    [No Abstract]   [Full Text] [Related]  

  • 2. Reducing the burden of disclosure for public biotech companies.
    Evans R; Kessel M
    Nat Biotechnol; 2014 May; 32(5):419-20. PubMed ID: 24811509
    [No Abstract]   [Full Text] [Related]  

  • 3. Bid to limit prices on drugs using 'public' discoveries.
    Wadman M
    Nature; 1998 May; 393(6683):297. PubMed ID: 9620788
    [No Abstract]   [Full Text] [Related]  

  • 4. The policy outlook from the Hill.
    Vastag B
    Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381
    [No Abstract]   [Full Text] [Related]  

  • 5. Putting your best mode forward.
    Tsao YR; Tabtiang RK
    Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
    [No Abstract]   [Full Text] [Related]  

  • 6. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 8. Industrial health research in Canada.
    Morin Y
    CMAJ; 2007 Jun; 176(12):1734; author reply 1734. PubMed ID: 17548390
    [No Abstract]   [Full Text] [Related]  

  • 9. Sarbanes-Oxley rules to be relaxed?
    Lawrence S
    Nat Biotechnol; 2006 Jul; 24(7):731-2. PubMed ID: 16841042
    [No Abstract]   [Full Text] [Related]  

  • 10. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
    Westerlund L
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
    [No Abstract]   [Full Text] [Related]  

  • 11. Teva to acquire Chinese biogenerics manufacturer.
    Katsnelson A
    Nat Biotechnol; 2005 Jul; 23(7):765. PubMed ID: 16003343
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech firms concerned about drug pricing issues.
    Nagy K
    J Natl Cancer Inst; 1993 Dec; 85(24):1986-7. PubMed ID: 8246283
    [No Abstract]   [Full Text] [Related]  

  • 13. Spreading biotech dollars around Washington.
    Senior M
    Nat Biotechnol; 2013 Aug; 31(8):673-5. PubMed ID: 23929333
    [No Abstract]   [Full Text] [Related]  

  • 14. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 15. The perils of federalizing vaccine production.
    Kazman S; Miller HI
    Nat Biotechnol; 2002 Feb; 20(2):113. PubMed ID: 11821845
    [No Abstract]   [Full Text] [Related]  

  • 16. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 17. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 18. Patently absurd?
    Garber K
    Nat Biotechnol; 2006 Jul; 24(7):737-9. PubMed ID: 16841046
    [No Abstract]   [Full Text] [Related]  

  • 19. Public biotech in 2014--the numbers.
    Morrison C; Lähteenmäki R
    Nat Biotechnol; 2015 Jul; 33(7):703-9. PubMed ID: 26154007
    [No Abstract]   [Full Text] [Related]  

  • 20. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.